Pasithea Therapeutics logo

Pasithea TherapeuticsNASDAQ: KTTA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

15 September 2021

Next earnings report:

20 November 2024

Last dividends:

N/A

Next dividends:

N/A
$3.99 M
-95%vs. 3y high
11%vs. sector
-vs. 3y high
-vs. sector
-96%vs. 3y high
21%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Tue, 19 Nov 2024 21:00:00 GMT
$3.15-$0.00(0.00%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

KTTA Latest News

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
globenewswire.com09 September 2024 Sentiment: POSITIVE

Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
globenewswire.com03 September 2024 Sentiment: POSITIVE

Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.

Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?
InvestorPlace13 December 2023 Sentiment: NEGATIVE

Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tuesday up less than 1%.

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewsWire07 September 2023 Sentiment: POSITIVE

-- Attendees may request 1 x 1 meeting with management at [email protected] --  PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.

What type of business is Pasithea Therapeutics?

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

What sector is Pasithea Therapeutics in?

Pasithea Therapeutics is in the Healthcare sector

What industry is Pasithea Therapeutics in?

Pasithea Therapeutics is in the Biotechnology industry

What country is Pasithea Therapeutics from?

Pasithea Therapeutics is headquartered in United States

When did Pasithea Therapeutics go public?

Pasithea Therapeutics initial public offering (IPO) was on 15 September 2021

What is Pasithea Therapeutics website?

https://www.pasithea.com

Is Pasithea Therapeutics in the S&P 500?

No, Pasithea Therapeutics is not included in the S&P 500 index

Is Pasithea Therapeutics in the NASDAQ 100?

No, Pasithea Therapeutics is not included in the NASDAQ 100 index

Is Pasithea Therapeutics in the Dow Jones?

No, Pasithea Therapeutics is not included in the Dow Jones index

When was Pasithea Therapeutics the previous earnings report?

No data

When does Pasithea Therapeutics earnings report?

The next expected earnings date for Pasithea Therapeutics is 20 November 2024